Deutsche Bank (ETR:DBKGn) initiated coverage on Denali Therapeutics Inc. (NASDAQ: NASDAQ:DNLI) with a Buy rating and set a price target of $31.00. The new assessment comes as Denali's shares are seen ...

Acceptance follows resolution of third-party fill/finish manufacturing issuesFDA decision expected by July 10, 2025 TARRYTOWN, N.Y., Feb. 11, ...

Acceptance follows resolution of third-party fill/finish manufacturing issues FDA decision expected by July 10, 2025 TARRYTOWN, N.Y., Feb. 11, 2025 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc.

Sage Therapeutics Inc. pushed off questions about potential mergers or acquisitions during its first earnings call since ...

Vertex Pharmaceuticals expects another year of rapid growth in 2025, after achieving this in the fourth quarter and ...

Q32 Bio (Nasdaq: QTTB) has announced a corporate restructuring, shifting its focus entirely to the development of its lead ...

The Roivant subsidiary Kinevant is to discontinue further development of namilumab for the treatment of sarcoidosis.

The European Commission has granted marketing authorization in the European Union (EU) for acoramidis, under the brand name ...

META_DESC_INVESTMENT_IDEA ...

OrganiGram Holdings Inc (TSX:OGI). reported a significant improvement in its financial performance for the third quarter of fiscal year 2024, with a 25% year-over-year increase in net revenue. The ...

Data Disclaimer: The Nasdaq Indices and the Major Indices are delayed at least 1 minute. Sign up for the TradeTalks newsletter to receive your weekly dose of trading news, trends and education.

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world ...